AZNCF Financials 07/16/2014 18:03:57 AstraZeneca

AZNCF Financials 07/16/2014 18:03:57
AstraZeneca Plc
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 25,711,000 27,973,000 33,591,000 33,269,000
Cost of Revenue 5,261,000 5,393,000 6,026,000 6,389,000
Gross Profit 20,450,000 22,580,000 27,565,000 26,880,000
Operating Expenses
Research and Development 4,821,000 5,243,000 5,523,000 5,318,000
Sales, General and Admin. 11,917,000 9,189,000 10,730,000 10,068,000
Non-Recurring Items - - - -
Other - - - -
Operating Income 3,712,000 8,148,000 12,795,000 11,494,000
Income From Continuing Operations
Add'l Income/Expense Items 50,000 42,000 1,533,000 516,000
Earnings Before Interest and Tax 3,762,000 8,190,000 12,845,000 12,010,000
Interest Expense 495,000 544,000 562,000 1,033,000
Earnings Before Tax 3,267,000 7,646,000 12,283,000 10,977,000
Income Tax 696,000 1,376,000 2,333,000 2,896,000
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 2,571,000 6,270,000 9,950,000 8,081,000
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 2,571,000 6,270,000 9,950,000 8,081,000
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 2,571,000 6,270,000 9,950,000 8,081,000